Русский
№6-7 / 2023
REVIEWS |
|
|
L.A. Kramynin, L.V. Filatova, I.S. Zyuzgin, M.S. Motalkina, S.S. Elkhova, E.V. Dobrovolskaya, A.K. Kovyazin, T.Yu. Semiglazova
Primary mediastinal B-cell lymphoma: evolution and prospects for first-line therapy. Literature review
|
6-15 |
|
N.S. Besova
Conversion therapy for stage IV gastric cancer: a review of prognostic factors and patient selection criteria according to the literature data
|
16-27 |
|
Ya.A. Yakimenko, V.V. Kutukov, V.V. Antonyan, M.A. Gaziev
Gastrointestinal toxicity during therapy with 5-fluorouracil
|
28-35 |
|
M.E. Abramov, T.E. Tikhomirova, O.E. Ryabishina, A.A. Rumyantsev, A.S. Tyulandina
Gastrointestinal stromal tumors: prospects for drug therapy of metastatic or inoperable forms
|
36-41 |
|
V.F. Semiglazov, A.V. Komyakhov, S.S. Ereshchenko, T.T. Tabagua, L.P. Gigolaeva, A.I. Tseluyko, A.P. Tergoeva, M.D. Kazantseva, N.S. Amirov, V.V. Mortada, R.S. Pesotsky, D.A. Enaldieva, L.F. Shaikhelislamova, K.S. Nikolaev, E.K. Zhiltsova, P.V. Krivorotko
Treatment of locally advanced (T2-3N0-1M0) and early (T1-2N0M0) HER2-positive breast cancer (clinical experience)
|
42-47 |
|
O.O. Gordeeva, N.A. Meshcheryakova, A.A. Meshcheryakov
Lorlatinib in the treatment of ALK-positive non-small cell lung cancer
|
48-53 |
|
G.A. Khakimov, G.G. Khakimova, Kh.U. Musurmonov, Sh.G. Khakimova, G.P. Orifzhonova
Pelvic extrusion in patients with cervical cancer: clinical experience
|
54-58 |
ORIGINAL ARTICLES |
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, T.Yu. Semiglazova, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
|
59-67 |
|
S.V. Nedogoda, A.S. Salasyuk, I.N. Barykina, V.O. Lutova, E.A. Popova, M.Yu. Frolov
Clinical and economic study of the use of ibrutinib in combination with venetoclax in patients with chronic lymphocytic leukemia
|
68-80 |
|
L.R. Bogatyreva, N.S. Besova, G.S. Yunaev, I.A. Kurmukov, E.S. Obarevich, D.A. Gavrilova, A.V. Egorova, N.V. Lepkova, A.A. Tryakin
Cardiac toxicity of fluoropyrimidines in the treatment of solid gastrointestinal tumors
|
81-89 |
|
L.Yu. Trofimchuk, N.G. Afanasieva
Sentinel lymph node scintigraphy in skin melanoma: personal experience
|
90-93 |
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, S.S. Ereshchenko, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Analysis of the effectiveness of various neoadjuvant chemotherapy regimens in patients with T1-3N1-3M0 I–IIIC stage locally advanced breast cancer
|
94-100 |
|
G.M. Teletaeva, E.A. Degtiareva, S.A. Protsenko, D.Kh. Latipova, A.I. Semenova, A.V. Novik, T.Yu. Semiglazova
Anemia in adult cancer patients
|
101-109 |
|
M.V. Pchelintsev
Tapentadol is a new drug in an old group. An overview of the use of tapentadol in the treatment of pain in cancer patients
|
110-116 |
|
N.I. Mikhailov, A.M. Zaitsev, O.N. Kirsanova, S.A. Kisariev
Spontaneous regression of hormonally inactive pituitary adenoma: a clinical case and literature review
|
117-120 |
|
N.V. Dmitrieva, E.R. Mavlyavieva, Yu.V. Chernikova, E.V. Fedotov, T.Sh. Mirilashvili
Combination of sarcoidosis and sigmoid colon cancer: a clinical observation
|
121-124 |
